Company attributes
Other attributes
Chiasma Pharma is a biopharmaceutical company that develops oral drugs for treating orphan diseases. The company plans to employ its validated TPE® technology to expand its pipeline of oral therapeutic options for patients who are with rare diseases to use instead of painful and burdensome injections. It is improving the lives of patients who face challenges that are associated with injectable therapies for their chronic or rare diseases.
The team that has been set up by Chiasma has expertise in the development and commercialization needed to bring novel oral therapies to patients with chronic or rare diseases, to conquer their challenges that are associated with existing injectables.
Its proprietary Transient Permeability Enhancer (TPE®) technology has been designed to convert select peptide based injectables into oral formulations. By leveraging this technology, patients may be alleviated of the burdens that are associated with chronic injectable therapies.
